Method for screening for sequence that regulates display efficiency in polynucleotide presentation method

JPWO2023162983A5Active Publication Date: 2024-12-03NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024503175
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-08-17
Publication Date
2024-12-03
Estimated Expiration
2043-02-21

AI Technical Summary

Technical Problem

Current methods for screening sequences that modulate the display efficiency of polynucleotide display methods are cumbersome and lack accuracy, requiring repeated selections and being limited by library diversity, especially in phage display and mRNA display techniques.

Method used

A method involving the translation of a polynucleotide containing a polypeptide coding sequence and a random sequence using a cell-free translation system, followed by binding to a solid phase via a modifier, and selecting random sequences based on their enrichment rate to improve presentation efficiency.

Benefits of technology

This approach allows for more efficient and accurate screening of sequences that enhance display efficiency, independent of the polypeptide coding sequence, enabling higher protein expression levels and versatile application in producing functional molecules.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention addresses the problem of providing a method that can more easily screen for, with a higher precision, a sequence that regulates the presentation efficiency in a polynucleotide presentation method. The problem is solved by a method for screening for a sequence that regulates the presentation efficiency in a polynucleotide presentation method, the method comprising: (a) a step for binding a polynucleotide-polypeptide complex, obtained through translation by an acellular translation system from a polynucleotide including a polypeptide encoding sequence and random sequences, to a solid phase via a modification substance on the polypeptide in the polynucleotide-polypeptide complex; and (b) a step for selecting a random sequence by using, as an index, the ratio (concentration factor) of the emergence frequency of each of the random sequences in the polynucleotide-polypeptide complex bonded to the solid phase with respect to the emergence frequency of each of the random sequences in the polynucleotide.
Need to check novelty before this filing date? Find Prior Art

Description

Method for screening sequences that regulate the display efficiency of polynucleotide display methods

[0001] The present invention relates to a method for screening for a sequence that regulates the display efficiency of a polynucleotide display method, and the like.

[0002] Functional molecules with high affinity and specificity for a target are used as detection tools and therapeutic drug candidates. One method for creating such new functional molecules (peptides and proteins) is directed toward obtaining functional molecules from a highly diverse library, known as directed evolutionary molecular engineering. In directed evolutionary molecular engineering, the greater the diversity of the initial library used, the higher the probability of obtaining functional molecules with high affinity, so diversity is an important factor in directed evolutionary molecular engineering.

[0003] The diversity of the library varies greatly depending on the method used. The phage display method, which is widely used as a directed evolutionary molecular engineering method, requires transformation, so the diversity of the library is limited to 10 9 ~10 11 On the other hand, methods using cell-free translation systems such as mRNA display (this method and similar methods may be collectively referred to as "polynucleotide display" in this specification) do not involve E. coli transformation, and therefore are limited to approximately 10 13 It is possible to construct libraries with a wide range of diversity.

[0004] In mRNA display, a phenotype protein is displayed on mRNA, representing the genotype, via a puromycin linker (PuL). However, because PuL must be covalently bound to mRNA before translation, multiple reactions—transcription to mRNA, ligation with PuL, and translation—must be performed separately. Therefore, the inventors improved the mRNA display method and developed the TRAP display method, which enables simple and rapid selection. The TRAP display method uses a reconstituted cell-free translation system, known as the TRAP reaction system, that lacks RF1, to automatically generate mRNA-protein complexes from DNA templates. This allows the above multistep reactions to be performed continuously, thereby successfully shortening the selection time.

[0005] Diversity in TRAP display is expressed as the product of mRNA concentration, translation reaction volume, and protein display efficiency on mRNA. The mRNA concentration is limited by the ribosome concentration in the translation reaction solution (approximately 1 μM), and translation reaction solutions are expensive and limited in amount. Therefore, improving display efficiency is required to increase diversity.

[0006] Non-Patent Document 1 reports an attempt to obtain N- and C-terminal sequences that improve the display efficiency in mRNA display. In this previous study, a library in which both the N- and C-terminal sequences of VHH antibodies were randomized was prepared, followed by transcription to mRNA and protein display on mRNA in a cell-free translation system. From this library, only the mRNA-protein complexes were recovered by gel purification, thereby enriching N- and C-terminal sequences with high display efficiency. After several cycles of this selection, a combination of N- and C-terminal sequences that slightly increased the display efficiency (1.2-fold) in the mRNA display method was obtained. Non-Patent Document 2, similar to Non-Patent Document 1, also prepared a library in which the C-terminal sequences of scFvs were randomized, followed by transcription to mRNA and protein display on mRNA in a cell-free translation system. From this library, only the mRNA-protein complexes were recovered using beads immobilized with the phenotype scFv target, thereby enriching C-terminal sequences with high display efficiency. This resulted in the isolation of C-terminal sequences that improved the display efficiency by approximately threefold. However, these methods require repeated selection until a sequence with high display efficiency is obtained, and their versatility is unknown.

[0007] K. Takahashi, M. Sunohara, T. Terai, S. Kumachi, N. Nemoto, Enhanced mRNA-protein fusion efficiency of a single-domain antibody by selection of mRNA display with additional random sequences in the terminal translated regions. Biophysics and Physicobiology 14, 23-28 (2017).Y. Nagumo, K. Fujiwara, K. Horisawa, H. Yanagawa, N. Doi, PURE mRNA display for in vitro selection of single-chain antibodies. Journal of Biochemistry 159, 519-526 (2016).

[0008] An objective of the present invention is to provide a method for more easily and more accurately screening for sequences that regulate the display efficiency of polynucleotide display methods.

[0009] In light of the above-mentioned problems, the present inventors have conducted extensive research and have found that the above-mentioned problems can be solved by a method for screening for sequences that modulate the display efficiency of polynucleotide display, the method comprising: (a) binding a polynucleotide-polypeptide complex obtained by translating a polynucleotide containing a polypeptide coding sequence and a random sequence in a cell-free translation system to a solid phase via a modifying substance on the polypeptide in the polynucleotide-polypeptide complex; and (b) selecting a random sequence using as an index the ratio (enrichment factor) of the frequency of occurrence of each random sequence in the polynucleotide-polypeptide complex bound to the solid phase relative to the frequency of occurrence of each random sequence in the polynucleotide. Using this screening method, the present inventors have found sequences that improve the display efficiency of polynucleotide display, independent of the polypeptide coding sequence. Based on these findings, the present inventors have conducted further research and have completed the present invention. Specifically, the present invention encompasses the following aspects.

[0010] Item 1. A method for screening for a sequence that modulates the display efficiency of a polynucleotide display method, comprising: (a) binding a polynucleotide-polypeptide complex obtained by translating a polynucleotide comprising a polypeptide-coding sequence and a random sequence in a cell-free translation system to a solid phase via a modifying substance on the polypeptide in the polynucleotide-polypeptide complex; and (b) selecting a random sequence using as an index the ratio (enrichment factor) of the frequency of occurrence of each random sequence in the polynucleotide-polypeptide complex bound to the solid phase to the frequency of occurrence of each random sequence in the polynucleotide.

[0011] Item 2. The screening method according to Item 1, wherein in step (b), a random sequence with a high enrichment rate is selected as a sequence that improves display efficiency.

[0012] Item 3. The screening method according to Item 1 or 2, wherein in step (b), random sequences whose enrichment rates are in the top 10% are selected as sequences that improve display efficiency.

[0013] Item 4. The screening method according to any one of Items 1 to 3, wherein the modifying substance is at least one selected from the group consisting of biotin, a peptide tag, and a substance containing a readily reactive group.

[0014] Item 5. The screening method according to any one of Items 1 to 4, wherein the random sequence is located downstream of the polypeptide-encoding sequence.

[0015] Item 6. The screening method according to Item 5, wherein a linker sequence is disposed between the random sequence and the polypeptide-encoding sequence.

[0016] Item 7. The screening method according to Item 5 or 6, wherein a stop codon is located adjacent to or within the random sequence.

[0017] Item 8. A polynucleotide comprising a polypeptide coding sequence or a site for inserting a polypeptide coding sequence, sequence 1 which is 3 bases in length, sequence 2 which is 3 bases in length, and a stop codon, which are arranged in the following order from upstream: the polypeptide coding sequence or the site for inserting a polypeptide coding sequence, sequence 1, sequence 2, and the stop codon, wherein sequence 1 and sequence 2 are adjacent to each other, and sequence 1 is GGC, CGT, GGT, or AAA, and / or sequence 2 is CGA, AGC, AGA, ACA, CGT, AGT, GCA, AGG, GGT, CGC, GCT, GGC, CGG, ACT, GAT, GAC, ATG, CCA, CCG, CCT, CTA, or CTG.

[0018] Item 9. The polynucleotide of Item 8, wherein sequence 1 is GGC, CGT, GGT, or AAA, and sequence 2 is CGA, AGC, AGA, ACA, CGT, AGT, GCA, AGG, GGT, CGC, GCT, GGC, CGG, ACT, GAT, GAC, ATG, CCA, CCG, CCT, CTA, or CTG.

[0019] Item 10. The polynucleotide according to Item 8 or 9, wherein the contiguous sequence of Sequence 1 and Sequence 2 is GGCCGA, GGCAGA, GGCGCA, GGTAGA, GGCAGT, GGCAGC, GGCACA, GGCCGT, GGCGCT, GGCGAT, GGCACT, GGTCGA, GGCAGG, GGCACG, GGTGAC, GGTAGG, CGTCGA, GGTAGT, GGTCGT, GGCGGT, GGACGA, GGTGGT, GGTACA, GGTCGC, AATCGA, GGTAGC, or GCGCGA.

[0020] Item 11. The polynucleotide according to any one of Items 8 to 10, wherein said sequence 2 and said termination codon are adjacent to each other.

[0021] Item 12. A reagent comprising the polynucleotide according to any one of Items 8 to 11.

[0022] Item 13. The reagent according to Item 12, which is a reagent for polynucleotide display.

[0023] The present invention provides a method for more easily and accurately screening for sequences that regulate the display efficiency of polynucleotide display. Furthermore, the present invention provides polynucleotides useful as reagents for polynucleotide display, including sequences that improve the display efficiency of polynucleotide display, independent of polypeptide coding sequences. Furthermore, because the enrichment rate obtained from the N-terminal library reflects the efficiency of translation initiation, which is important for protein expression, this information is believed to enable control of protein expression levels. This is useful for the production of useful substances using cells and for highly efficient protein production.

[0024] A schematic diagram of the screening method for C-terminal random sequences in Test Example 1 is shown. A: The design of the library used is shown. A random sequence was added to the C-terminus of DNA encoding a monobody or anticalin. The random sequence consisted of codon 1, codon 2, and base 1, resulting in two mixed libraries, I and II. B: The procedure for the screening method used in this study is shown. After creating a DNA library by PCR, it was transcribed into mRNA, annealed with PuL, and translated in a TRAP reaction system. A portion of the library was recovered using biotin-streptavidin interaction. The libraries before and after recovery were sequenced, and the ratio of the occurrence frequency in each library was calculated. This value was used as the enrichment rate and as an index for predicting display efficiency. Data analysis and evaluation of the results of screening for C-terminal random sequences in Test Example 1 are shown. A: The enrichment rates for each C-terminal sequence in the monobody library and the anticalin library are plotted separately. The respective distribution maps are shown in the lower panel. The locations of the sequences used in B are shown in the distribution map. Figure 1 shows data analysis and evaluation of the results of screening for C-terminal random sequences in Test Example 1. A: The display efficiency of monobodies with the 19 C-terminal sequences listed in Table 1 added was measured. The graph on the lower left shows the plot of display efficiency versus enrichment rate. Error bars represent standard deviation (N = 3). The calculation method for display efficiency is described in the lower right. Figure 1 shows the results of measuring display efficiency when three C-terminal sequences were added to upstream sequences other than the T Monobody. c1 is the C-terminal sequence with the highest enrichment rate, c16 is in the top 2.75%, and c13 is at 34.69%. Error bars represent standard deviation (N = 3). A: Monobody library. B: Anticalin. C: Macrocyclic peptide library. A heat map (Test Example 1) showing the enrichment rate of each C-terminal sequence in the monobody library represented by color. A schematic diagram of the screening method for N-terminal random sequences in Test Example 3 is shown. Data analysis of the results of screening for N-terminal random sequences in Test Example 3 is shown.A: To confirm reliability, two independent experiments were repeated using the monobody library, and the enrichment rate of each N-terminal sequence in the obtained data was plotted. B: The enrichment rate of each N-terminal sequence was plotted for the data obtained for two types of sequences, monobody and anticalin. C: The enrichment rate of each N-terminal sequence was plotted for the data obtained for two types of sequences, including the SD sequence. A heat map (Test Example 4) is shown, in which the enrichment rate of each C-terminal sequence in the monobody library is represented by color.

[0025] In this specification, the expressions "contain" and "comprise" include the concepts of "contain," "comprise," "consist essentially of," and "consist only of."

[0026] 1. Screening Method In one aspect, the present invention relates to a method for screening for a sequence that modulates the display efficiency of a polynucleotide display method (sometimes referred to herein as the "screening method of the present invention"), which comprises steps (a) and (b). This method is described below.

[0027] Step (a) is a step of binding a polynucleotide-polypeptide complex obtained by translation in a cell-free translation system from a polynucleotide comprising a polypeptide-encoding sequence and a random sequence (sometimes referred to as a "screening polynucleotide" herein) to a solid phase via a modifying substance on the polypeptide in the polynucleotide-polypeptide complex.

[0028] The polypeptide-encoding sequence contained in the screening polynucleotide is not particularly limited as long as it is a nucleotide sequence that encodes a polypeptide, such as an antibody, monobody, enzyme, ligand, receptor, structural protein, linear polypeptide, oligopeptide, or fragment thereof.

[0029] The random sequence contained in the polynucleotide for screening is the sequence to be screened. The polynucleotide for screening is a mixture containing multiple types of polynucleotides with different random sequences. The number of types of polynucleotides for screening (number of types of random sequences) is, for example, 10 1 ~10 11 The lower limit of this number is, for example, 10 2 , 10 3 The upper limit of the number can be, for example, 10 10 , 10 9 , 10 8 , 10 7 , 10 6 , 10 5 , 10 4 It can be.

[0030] The position of the random sequence is not particularly limited. The random sequence can be located upstream of the polypeptide-encoding sequence (i.e., on the N-terminal side when translated into a polypeptide) or downstream of the polypeptide-encoding sequence (i.e., on the C-terminal side when translated into a polypeptide). In a preferred embodiment of the present invention, the random sequence is located downstream of the polypeptide-encoding sequence. This makes it possible to screen for a sequence that can regulate the display efficiency regardless of the type or sequence of the polypeptide encoded by the upstream polypeptide-encoding sequence.

[0031] In the polynucleotide for screening, the random sequence may be present at only one position, or may be present at two or more positions that are not adjacent to each other. In one embodiment, the random sequence contains a stop codon. In this case, the random sequence 1, the stop codon, and the random sequence 2 are arranged in this order.

[0032] The length of the random sequence (base length: if present at two or more positions, the total length of all positions) is not particularly limited and is, for example, 3 to 200, preferably 3 to 100, more preferably 3 to 50, even more preferably 4 to 30, still more preferably 5 to 20, and particularly preferably 5 to 10.

[0033] As used herein, the term "stop codon" refers to a codon that is not contained in a tRNA having a corresponding anticodon in the reaction system, and is not particularly limited thereto. Specific examples of stop codons include codons to which no amino acid is assigned in a codon table, such as TAA, TAG, and TGA, as well as codons corresponding to the anticodon of a tRNA that is not added to the reaction system, and codons containing modified bases.

[0034] The configuration of the screening polynucleotide is not particularly limited as long as it can be translated in a cell-free translation system to synthesize a polypeptide encoded by the polypeptide-coding sequence. When the polypeptide-coding sequence does not have an initiation codon and / or a termination codon, the screening polynucleotide has an initiation codon upstream of the polypeptide-coding sequence and / or a termination codon downstream of the polypeptide-coding sequence.

[0035] When a random sequence is located downstream of a polypeptide-encoding sequence in a screening polynucleotide, it is preferable that another sequence be located between the polypeptide-encoding sequence and the random sequence. The other sequence may preferably be a linker sequence. The linker sequence is not particularly limited as long as it has a flexible chain structure, and examples thereof include linker sequences containing glycine and / or serine. The length (base length) of the other sequence is, for example, 3 or more, preferably 4 or more. The upper limit of the length is not particularly limited, but may be, for example, 100, 50, 30, or 20.

[0036] The screening polynucleotide can be used in either a prokaryotic or eukaryotic cell translation system as a cell-free translation system. From the viewpoint of simplicity, it is preferable to use a prokaryotic cell translation system as the cell-free translation system. When the screening polynucleotide is used in a prokaryotic cell translation system, it preferably has a Shine-Dalgarno sequence (SD sequence) upstream of the start codon. Furthermore, when the screening polynucleotide is used in a eukaryotic cell translation system, it preferably has a Kozak sequence, a 5' cap, and an internal ribosome entry site (IRES).

[0037] A preferred embodiment of the screening polynucleotide is a polynucleotide comprising a sequence consisting of a polypeptide coding sequence, a random sequence, and a stop codon, arranged in this order from upstream to downstream. In this embodiment, the random sequence and the stop codon are preferably adjacent to each other, and a linker sequence is preferably arranged between the polypeptide coding sequence and the random sequence.

[0038] Another preferred embodiment of the screening polynucleotide is a polynucleotide comprising a sequence consisting of, from upstream to downstream, an initiation codon, a random sequence, a polypeptide-encoding sequence, and a termination codon. In this embodiment, the initiation codon and the random sequence are preferably adjacent to each other.

[0039] The screening polynucleotide may comprise a peptide tag coding sequence adjacent to the polypeptide coding sequence. In one embodiment, the peptide tag encoded by the peptide tag coding sequence can be used as a modifier on the polypeptide described below and can be bound to a solid phase. Examples of peptide tags include His tags, FLAG tags, Halo tags, GST tags, MBP tags, HA tags, Myc tags, V5 tags, and PA tags.

[0040] The type of nucleotide constituting the screening polynucleotide is not particularly limited as long as it is capable of synthesizing a polypeptide in a translation system. The screening polynucleotide may preferably be RNA (mRNA).

[0041] The screening polynucleotide can be obtained according to or in accordance with a known method, for example, by transcription in a cell-free transcription system from a DNA vector encoding the screening polynucleotide.

[0042] The polynucleotide-polypeptide complex is obtained by translating the screening polynucleotide in a cell-free translation system. The polynucleotide-polypeptide complex is a complex between the screening polynucleotide and / or its complementary strand (e.g., cDNA, etc.) and the polypeptide encoded by the polypeptide-coding sequence in the screening polynucleotide. The complex can be obtained according to or in accordance with known methods. For example, this can be achieved by attaching puromycin downstream of the stop codon of the screening polynucleotide. Puromycin may also be attached to the screening polynucleotide via a linker composed of a peptide or nucleic acid. By attaching puromycin to the region downstream of the stop codon of the screening polynucleotide, the ribosome that translated the polypeptide-coding sequence of the screening polynucleotide incorporates puromycin, forming a complex between the screening polynucleotide and the polypeptide.

[0043] As used herein, the term "cell-free translation system" refers to a translation system that does not contain cells. Examples of cell-free translation systems that can be used include Escherichia coli extracts, wheat germ extracts, rabbit erythrocyte extracts, and insect cell extracts. Alternatively, reconstituted cell-free translation systems constructed by reconstituting purified ribosomal proteins, aminoacyl-tRNA synthetases (aaRSs), ribosomal RNA, amino acids, rRNA, GTP, ATP, translation initiation factors (IFs), elongation factors (EFs), release factors (RFs), and ribosome recycling factors (RRFs), as well as other factors necessary for translation, may also be used. Systems containing RNA polymerase may also be used to perform transcription from DNA. Commercially available cell-free translation systems include E. coli-derived systems such as Roche Diagnostics' RTS-100 (registered trademark), reconstituted translation systems such as PGI's PURESYSTEM (registered trademark) and New England BioLabs' PURExpress® In Vitro Protein Synthesis Kit, and wheat germ extract-based systems such as those from Zoigene and Cell-Free Sciences.Furthermore, systems using Escherichia coli ribosomes are known, for example, as described in the following documents: H.F. Kung et al., 1977, The Journal of Biological Chemistry, Vol. 252, No. 19, 6889-6894; M.C. Gonza et al., 1985, Proceedings of the National Academy of Sciences of the United States of America, Vol. 82, 1648-1652; M.Y. Pavlov and M. Ehrenberg, 1996, Archives of Biochemistry and Biophysics, Vol. 328, No. 1, 9-16; Y. Shimizu et al., 2001, Nature Biotechnology, Vol. 19, No. 8, 751-755; H. Ohashi et al., 2007, Biochemical and Biophysical Research Communications, Vol. 352, No. 1, 270-276. The cell-free translation system allows expression products to be obtained in a highly pure form without purification. The cell-free translation system of the present invention may be used not only for translation but also for transcription by adding factors necessary for transcription.

[0044] Polynucleotide-polypeptide complexes contain a modifying substance on the polypeptide for solid phase binding. Modifiers are not particularly limited as long as they can be used for solid phase binding, and examples include biotin, peptide tags, and substances containing easily reactive groups. Biotin can be bound to solid phases modified with avidins (e.g., streptavidin). Peptide tags can be bound to solid phases modified with substances that have affinity for them (e.g., anti-HA antibodies for HA tags, metals such as nickel for His tags, anti-FLAG antibodies for FLAG tags, and glutathione for GST tags). Easily reactive groups include ethynyl groups, vinyl groups, azide groups, epoxy groups, aldehyde groups, and oxylamino groups. Ethynyl groups are known to undergo 1,3-dipolar cycloaddition with azide groups to form 1,2,3-triazole rings. Vinyl groups react with thiol groups to form bonds. Epoxy groups react with amino and thiol groups to form bonds. Aldehyde groups react with amino groups to form Schiff bases, which can be reduced to form bonds. Oxylamino groups react with ketone and aldehyde groups to form oximes. Azide groups are known to undergo 1,3-dipolar cycloaddition with ethynyl groups to form 1,2,3-triazole rings. These reactions can be used to bond easily reactive groups to solid phases modified with the corresponding functional groups.

[0045] The modifying substance can be attached to the polypeptide according to or in accordance with known methods. For example, in the case of a peptide tag, as described above, the polypeptide can be modified with the peptide tag by arranging the peptide tag coding sequence adjacent to the polypeptide coding sequence in the screening polynucleotide. Furthermore, in the case of a substance containing biotin or a reactive group, the polypeptide can be modified with these substances by introducing the obtained tRNA by acylation of any tRNA with an amino acid containing these substances into a cell-free translation system.

[0046] The above tRNA can be prepared using Flexizyme. Flexizyme is an artificial aminoacylation RNA catalyst capable of acylation of any tRNA with any amino acid or hydroxy acid. By using Flexizyme instead of the aminoacyl-tRNA synthesized by natural aminoacyl-tRNA synthetases, the genetic code can be rewritten by associating a desired amino acid or hydroxy acid with any codon. This process is called codon reallocation. Codon reallocation can be achieved by freely removing components of a translation system according to the purpose and reconstituting only the necessary components. For example, when a translation system from which a specific amino acid has been removed is reconstituted, the codon corresponding to that amino acid becomes a vacant codon that does not encode any amino acid. Therefore, by using Flexizyme or other methods to link any amino acid to a tRNA with an anticodon complementary to the vacant codon and then translating the resulting tRNA, the vacant codon encodes the desired amino acid. This results in a peptide being translated in which the vacant amino acid has been introduced in place of the removed amino acid.

[0047] The solid phase material is not particularly limited and can be selected from, for example, organic polymer compounds, inorganic compounds, biopolymers, etc. Examples of organic polymer compounds include latex, polystyrene, polypropylene, etc. Examples of inorganic compounds include magnetic materials (iron oxide, chromium oxide, ferrite, etc.), silica, alumina, glass, etc. Examples of biopolymers include insoluble agarose, insoluble dextran, gelatin, cellulose, etc. The solid phase material can be one type alone or a combination of two or more types.

[0048] The shape of the solid phase is not particularly limited, and examples thereof include particles, microplates, microtubes, test tubes, and membranes.

[0049] The binding of the polynucleotide-polypeptide complex to the solid phase can be carried out according to or in accordance with known methods, depending on the type of modifier on the polypeptide, the type of modifier on the solid phase, etc. Specifically, the polynucleotide-polypeptide complex and the solid phase can be bound by contacting them in a solution of an appropriate composition. After binding, it is preferable to wash the polynucleotide-polypeptide complex and the solid phase with a solution or solvent that does not dissociate them.

[0050] Step (b) is a step of selecting random sequences using as an index the ratio (enrichment factor) of the frequency of occurrence of each random sequence in the polynucleotide-polypeptide complex bound to the solid phase to the frequency of occurrence of each random sequence in the screening polynucleotide.

[0051] The occurrence frequency (occurrence frequency X) of each random sequence in the screening polynucleotide can be, for example, the ratio of the number of molecules of the screening polynucleotide having each random sequence to (X1) the number of molecules of the screening polynucleotide before being subjected to translation in a cell-free translation system, (X2) the number of molecules of the screening polynucleotide in a mixture containing a polynucleotide-polypeptide complex before being subjected to binding to a solid phase (this includes screening polynucleotides from which the polypeptide has not been translated), or (X3) the number of molecules of the screening polynucleotide in a mixture that has been subjected to binding to a solid phase but has not been subjected to solid-liquid separation (this includes screening polynucleotides from which the polypeptide has not been translated). For example, when the screening polynucleotides are 10 different from each other in random sequence, the ratio of the number of molecules of the screening polynucleotide having each random sequence to (X3) the number of molecules of the screening polynucleotide in a mixture that has been subjected to binding to a solid phase but has not been subjected to solid-liquid separation (this includes screening polynucleotides from which the polypeptide has not been translated). 4 A mixture containing a variety of polynucleotides, and the number of polynucleotide molecules having a certain random sequence (random sequence A) in the mixture is 10 2 If there are 10, the occurrence frequency X of random sequence A is 1% (= (10 2 / 10 4 ) × 100 (%).

[0052] The frequency of occurrence (occurrence frequency Y) of each random sequence in a polynucleotide-polypeptide complex bound to a solid phase can be, for example, the ratio of the number of molecules of screening polynucleotides having each random sequence to (Y1) the number of molecules of screening polynucleotides in a polynucleotide-polypeptide complex obtained by binding to a solid phase and then undergoing solid-liquid separation, or (Y2) the number of molecules of screening polynucleotides in a polynucleotide-polypeptide complex obtained by binding to a solid phase and then undergoing solid-liquid separation and washing.

[0053] The occurrence frequency of each random sequence can be measured and calculated according to or in accordance with a known method. The occurrence frequency can be measured and calculated, for example, by sequence analysis using a next-generation sequencer. In this case, the above-mentioned "number of molecules" can be replaced with the "number of reads" obtained by the next-generation sequencer.

[0054] In step (b), random sequences are selected using the ratio of occurrence frequency Y to occurrence frequency X (enrichment rate) as an index. In the present invention, it has been found that the enrichment rate correlates with the display efficiency of polynucleotide display methods, and based on this, it has been found that sequences that modulate display efficiency can be screened in step (b).

[0055] Polynucleotide display is a technique for artificially evolving molecules by in vitro selection using a cell-free translation system. Examples of polynucleotide display methods include mRNA display, cDNA display, ribosome display, and TRAP display. Display efficiency can be measured according to or in accordance with known methods. For example, the display efficiency can be measured by electrophoresing the reaction product after translation of mRNA encoding the protein to be displayed in a cell-free translation system, and then measuring the band intensity according to the formula shown in Figure 2B below.

[0056] In step (b), for example, a random sequence with a high enrichment rate can be selected to screen for sequences that improve display efficiency. Here, "high enrichment rate" refers to a sequence with a high enrichment rate when all random sequences are sorted in order of enrichment rate. In a preferred embodiment of the present invention, a random sequence with an enrichment rate in the top 30% (preferably 20%, more preferably 10%, even more preferably 5%, and even more preferably 3%) can be selected as a sequence that improves display efficiency. In another preferred embodiment of the present invention, a random sequence with an enrichment rate of 1.5 or higher (preferably 2 or higher, more preferably 2.5 or higher, and even more preferably 3 or higher) can be selected as a sequence that improves display efficiency.

[0057] 2. Polynucleotides and Reagents In one aspect, the present invention relates to a polynucleotide (sometimes referred to herein as the "polynucleotide of the present invention") comprising a polypeptide coding sequence or a site for inserting a polypeptide coding sequence, a 3-base sequence 1, a 3-base sequence 2, and a stop codon, arranged in the following order from upstream: polypeptide coding sequence or a site for inserting a polypeptide coding sequence, sequence 1, sequence 2, and stop codon, with sequence 1 and sequence 2 adjacent to each other, and sequence 1 being GGC, CGT, GGT, or AAA, and / or sequence 2 being CGA, AGC, AGA, ACA, CGT, AGT, GCA, AGG, GGT, CGC, GCT, GGC, CGG, ACT, GAT, GAC, ATG, CCA, CCG, CCT, CTA, or CTG. Furthermore, in another aspect, the present invention relates to a reagent (sometimes referred to herein as the "reagent of the present invention") comprising the polynucleotide of the present invention. These are described below.

[0058] In a more preferred embodiment of the present invention, sequence 1 is GGC, CGT, GGT, or AAA (or GGC, CGT, or GGT), and sequence 2 is CGA, AGC, AGA, ACA, CGT, AGT, GCA, AGG, GGT, CGC, GCT, GGC, CGG, ACT, GAT, GAC, ATG, CCA, CCG, CCT, CTA, or CTG (or GA, AGC, AGA, ACA, CGT, AGT, GCA, AGG, GGT, CGC, GCT, GGC, CGG, ACT, GAT, or GAC).

[0059] In a more preferred embodiment of the present invention, the contiguous sequences of SEQ ID NO:1 and SEQ ID NO:2 are GGCCGA, GGCAGA, GGCGCA, GGTAGA, GGCAGT, GGCAGC, GGCACA, GGCCGT, GGCGCT, GGCGAT, GGCACT, GGTCGA, GGCAGG, GGCACG, GGTGAC, GGTAGG, CGTCGA, GGTAGT, GGTCGT, GGCGGT, GGACGA, GGTGGT, GGTACA, GGTCGC, AATCGA, GGTAGC, GCGCGA.

[0060] In an even more preferred embodiment of the present invention, the contiguous sequences of SEQ ID NO:1 and SEQ ID NO:2 are GGCCGA, GGCAGA, GGTAGA, GGCACA, GGCCGT, GGCAGT, GGCAGC, GGCAGG, GGTCGA, GGCGCT, GGCACT, GGCGCA, GGTAGG.

[0061] In a particularly preferred embodiment of the present invention, the contiguous sequences of SEQ ID NO:1 and SEQ ID NO:2 are GGCCGA, GGCAGA, GGTAGA, GGCCGT, GGCAGT, GGCAGC, GGTCGA, GGCGCT, GGCACT.

[0062] In the polynucleotide of the present invention, sequence 2 is preferably located relatively close to the stop codon, and the base length between sequence 2 and the stop codon is preferably 0 to 6, more preferably 0 to 3, and even more preferably 0 (i.e., sequence 2 and the stop codon are adjacent to each other). This can further improve the display efficiency.

[0063] In the polynucleotide of the present invention, the base immediately downstream of the stop codon is more preferably T or C.

[0064] The site for inserting a polypeptide coding sequence can be, for example, a restriction enzyme site, and preferably, a multicloning site containing multiple restriction enzyme sites.

[0065] The polynucleotide of the present invention can be, for example, an mRNA, or a vector for expressing said mRNA.

[0066] For other configurations of the polynucleotide of the present invention, the configurations of the polynucleotide for screening described above can be adopted.

[0067] The reagent of the present invention is preferably a reagent for a polynucleotide display method, which is as described above.

[0068] In the reagent of the present invention, the polynucleotide of the present invention can be in the form of a composition containing it. The composition may contain other components as necessary. Examples of other components include bases, carriers, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, moisturizers, colorants, fragrances, chelating agents, etc.

[0069] The reagent of the present invention can be in the form of a kit. In this case, the reagent (reagent kit) of the present invention may include instruments, reagents, etc. that can be used in the polynucleotide display method. Examples of instruments include test tubes, microplates, particles, latex particles, purification columns, epoxy-coated slides, and gold colloid-coated slides. Examples of reagents include buffer solutions, cell-free transcription reagents, and cell-free translation reagents.

[0070] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.

[0071] Materials and Methods (1) Oligonucleotide and DNA Sequences Used The sequence numbers of the oligonucleotides and DNA sequences used in this study are shown in Table 1.

[0072]

[0073] (2) Construction of a DNA library with random C-terminal sequences. A PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM SD8-MQANSGS-MonoS(H).F61, 0.375 μM MonoS(H)-GGG.R32, 0.2 nM MonoS(H)SSS-HA, 2 nM Pfu-S DNA polymerase) was prepared and subjected to 10 cycles of PCR. This was designated Template 1. Next, PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM T7SD8M2.F44, 0.276 μM MonoS(H)-VVN2N1.R49 or 0.031 μM MonoS(H)-VVN1N2.R50, 0.375 nM Template 1, and 2 nM Pfu-S DNA polymerase) was prepared and subjected to 9 cycles of PCR. After PCR, the DNA was treated with phenol-chloroform and precipitated with isopropanol. This was designated as the VVN monobody DNA. Monobody NNN DNA was prepared in the same manner as above, using MonoS(H)-NNN3.R53 instead of MonoS(H)-VVN2N1.R49.

[0074] A PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM SD8-Lcn.F62, 0.375 μM Lcn-GGG.R33, 0.375 nM pQ106-Ant-wt, and 2 nM Pfu-S DNA polymerase) was prepared and subjected to 18 cycles of PCR. This was designated Template 2. Next, PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM T7SD8M2.F44, 0.276 μM Lcn-VVN2N1.R49 or 0.031 μM Lcn-VVN1N2.R50, 0.375 nM Template 2, and 2 nM Pfu-S DNA polymerase) was prepared and subjected to 9 cycles of PCR. After PCR, the DNA was treated with phenol-chloroform and precipitated with isopropanol. This was designated Anticalin VVN DNA.

[0075] (3) Screening for C-terminal random sequences. Monobody VVN DNA, Monobody NNN DNA, and Anticalin VVN DNA were transcribed into mRNA using T7 RNA polymerase, followed by phenol-chloroform treatment and two rounds of isopropanol precipitation. These were designated Monobody VVN mRNA, Monobody NNN mRNA, and Anticalin VVN mRNA, respectively. The mRNA-PuL complex was prepared by incubating the annealing solution (6.67 μM Monobody VVN mRNA or Monobody NNN mRNA or Anticalin VVN mRNA, 4 μM Hex-PuL-an21-3, 25 mM HEPES-K pH 7.8, 200 mM AcOK) at 95°C for 3 minutes and then at 25°C for 5 minutes. This was then transcribed using a reconstituted cell-free translation system (16 μM Biotin-Phe-tRNA except for RF1 and Formyl donor). fMet CAU The mixture was added to a 4-μL reaction solution (containing 1 μM of mRNA-PuL complex: fc) and incubated at 37°C for 30 minutes. 0.8 μL of 100 mM EDTA, pH 8.0, was added to the reaction solution (4 μL).

[0076] 0.2 pmol of the mRNA-protein complex prepared above was added to 20 μL of Dynabeads M-280 streptavidin (Thermo Fisher Scientific) and mixed by rotation at 25°C for 5 minutes. The mRNA-protein complex was then recovered and washed with 50 μL of HBST (50 mM Hepes-KOH (pH 7.5), 300 mM NaCl, 0.05% (v / v) Tween 20) for 60 seconds, followed by 50 μL of HBS (50 mM Hepes-KOH (pH 7.5), 300 mM NaCl) for 60 seconds.

[0077] To 0.02 pmol of unrecovered mRNA-protein complex (before recovery) and the total amount of recovered mRNA-protein complex (after recovery), 10 μL of RT primer annealing solution (5 μM an21-3.R21, 25 mM HEPES-K pH 7.8, 200 mM AcOK) was added, and the mixture was incubated at 95°C for 2 minutes and then at 25°C for 30 seconds. After recovery, only the supernatant after centrifugation was collected. Then, 10 μL of 2xRT mix (124 mM Tris-HCl (pH 8.4), 62.2 mM MgCl2, 186 mM KCl, 13.7 mM dithiothreitol (DTT), 1.24 mM dNTPs, 0.8% (v / v) in-house moloney murine leukemia virus reverse transcriptase (HMLV)) was added, and the reverse transcription reaction was carried out at 42°C for 30 minutes.

[0078] 180 μL of 1x PCR dNTPs (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2 mM MgSO4, 0.22 mM dNTPs) was added to the reverse transcription product. An 85 μL aliquot was added to an equal volume of 2x PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 4% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 4 nM Pfu-S DNA polymerase) and 1.28 μL of primer mix [(25 μM MonoMidF22, 25 μM MonoMidF22+2, 50 μM an21-3barcode11 or an21-3barcode12) or (25 μM LcnMidF22, 25 μM LcnMidF22+2, 50 μM an21-3barcode13 or an21-3barcode14)], and PCR was performed for 12 cycles (13 cycles after Anticalin recovery). After PCR, the DNA was treated with phenol-chloroform and precipitated with isopropanol. Sequence analysis of the DNA was performed using a next-generation sequencer (Macrogen Japan).

[0079] (4) Calculation of enrichment rate. The DNA read by sequence analysis was clustered by C-terminal sequence, and the total number of reads was counted. The percentage of the number of reads for each C-terminal sequence relative to the total number of reads for the entire library was calculated as the frequency of occurrence, and the ratio of the frequency of occurrence after recovery to the frequency of occurrence before recovery was calculated as the enrichment rate. A distribution of the enrichment rates of C-terminal sequences was also created.

[0080] (5) Preparation of mRNA with C-terminal sequence added The combinations of primers, template DNA, and cycle numbers used below are shown in Table 2.

[0081]

[0082] A PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM Forward primer A, 0.375 μM Reverse primer A, 0.375 nM Template A, and 2 nM Pfu-S DNA polymerase) was prepared and subjected to W cycles of PCR. Next, a PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM Forward primer B, 0.375 μM Reverse primer B, 0.375 nM Template B, and 2 nM Pfu-S DNA polymerase) was prepared and subjected to Z-cycle PCR. After PCR, the DNA was treated with phenol-chloroform and then precipitated with isopropanol.

[0083] This was transcribed into mRNA using T7 RNA polymerase, treated with phenol-chloroform, and precipitated twice with isopropanol, then gel purified, treated with phenol-chloroform, and precipitated again with isopropanol.

[0084] (6) Display Efficiency Measurement The mRNA-PuL complex was prepared by incubating the annealing solution (4.8 μM mRNA, 4 μM Hex-PuL-an21-3, 25 mM HEPES-K pH 7.8, 200 mM AcOK) at 95°C for 3 minutes and then at 25°C for 5 minutes. This was added to the reconstituted cell-free translation system (excluding RF1) (mRNA-PuL complex: fc 1 μM) and incubated at 37°C for 30 minutes. However, for the macrocyclic peptide library, 10 μM N-Chloroacetyl-L-Phe-tRNA was added except for RF1 and Formyl donor. fMet CAUA reconstituted cell-free translation system containing newly added 5′-T7 RNA polymerase was used. The translation reaction for the monobody library was carried out at 37°C for 10 minutes. To measure the display efficiency with DNA starting DNA, DNA (fc 5 nM) and Hex-PuL-an21-3 (fc 1 μM) were added to the reconstituted cell-free translation system (excluding RF1 and containing T7 RNA polymerase) and incubated at 37°C for 30 minutes.

[0085] 11 μL of gel loading buffer (62.5 mM Tris-HCl pH 6.8, 5 mM DTT, 0.05% (w / v) SDS, 10 mM MgCl2, 20% (v / v) glycerol) was added to 1 μL of the sample before and after the translation reaction. 2 μL of the resulting mixture was electrophoresed on 8% PAGE (0.375 M Tris-HCl pH 8.8, 6 M urea, 0.05% SDS). For the macrocyclic peptide library, 8% PAGE (0.45 M Tris-HCl pH 8.8, 6 M urea, 0.05% SDS) was used. Bands were confirmed by HEX fluorescence imaging using a ChemiDoc MP Imaging System (Bio-Rad). Display efficiency was calculated based on the band intensity in the post-translation lanes as described in Figure 2B.

[0086] (7) Construction of a DNA library with N-terminal random sequences. A PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM MonoS(H)SSS.F26, 0.375 μM HATag-G4S.R48, 0.2 nM MonoS(H)SSS-HA, 2 nM Pfu-S DNA polymerase) was prepared and subjected to 10 cycles of PCR. This was designated Template 3. Next, a PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM MonoS(H)NNW3SSS.F58, 0.375 μM G5S-4Gan21-3.R42, 0.375 nM Template 3, and 2 nM Pfu-S DNA polymerase) was prepared and used for 9 cycles. This was designated Template 4. Next, a PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM T7SD8M2.F44, 0.375 μM G5S-4Gan21-3.R42, 0.375 nM Template 4, and 2 nM Pfu-S DNA polymerase) was prepared and subjected to 10 cycles of PCR. After PCR, the DNA was treated with phenol and chloroform and precipitated with isopropanol. This was used as MonobodyNNW DNA. AnticalinNNW DNA was also prepared in a similar manner.

[0087] A PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM catMonoS(H)NNW3SSS.F60, 0.375 μM G5S-4Gan21-3.R42, 0.375 nM Template 3, and 2 nM Pfu-S DNA polymerase) was prepared and used for nine cycles. This was designated Template 5. Next, a PCR reaction mixture (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2% (v / v) DMSO, 2 mM MgSO, 0.2 mM each dNTP, 0.375 μM T7SDCATM.F46, 0.375 μM G5S-4Gan21-3.R42, 0.375 nM Template 4, and 2 nM Pfu-S DNA polymerase) was prepared and subjected to 10 cycles of PCR. After PCR, the DNA was treated with phenol and chloroform and then precipitated with isopropanol. This was designated catMonobodyNNWDNA.

[0088] (8) Screening for N-terminal random sequences. MonobodyNNWDNA, catMonobodyNNWDNA, and AnticalinNNWDNA were transcribed into mRNA using T7 RNA polymerase, followed by phenol-chloroform treatment and two rounds of isopropanol precipitation. These were designated MonobodyNNWmRNA, catMonobodyNNWmRNA, and AnticalinNNWDNA, respectively. The mRNA-PuL complex was prepared by incubating the annealing solution (6.67 μM MonobodyNNWmRNA or catMonobodyNNWmRNA or AnticalinNNWDNA, 4 μM Hex-PuL-an21-3, 25 mM HEPES-K pH 7.8, 200 mM AcOK) at 95°C for 3 minutes and then at 25°C for 5 minutes. This complex was then added to a reconstituted cell-free translation system (excluding RF1) (mRNA-PuL complex: fc 1 μM) and incubated at 37°C for 30 minutes. To the reaction mixture (4 μL), 0.8 μL of 100 mM EDTA pH 8.0 was added. 2.4 μL of 3xRT mix (150 mM Tris-HCl (pH 8.4), 75 mM MgCl2, 225 mM KCl, 16.5 mM dithiothreitol (DTT), 1.5 mM dNTPs, 0.12% (v / v) in-house moloney murine leukemia virus reverse transcriptase (HMLV), 7.5 μM G4S.R19) was added, and the reverse transcription reaction was carried out at 42°C for 15 minutes. The reaction mixture was then transferred to a Zeba® buffer solution equilibrated with HBST (50 mM Hepes-KOH (pH 7.5), 300 mM NaCl, 0.05% (v / v) Tween 20). TM Buffer exchange was performed by filtration using Spin Desalting Columns 7K MWCO (Thermo Scientific).

[0089] 3.2 pmol of the reverse-transcribed mRNA-protein complex prepared above was mixed with 1 μL of Anti-HA tag mAb (TANA2) (Medical & Biological Laboratories Co., Ltd.) and incubated at 25°C for 30 minutes. TM 20 μL of Protein G for immunoprecipitation (Thermo Fisher Scientific) was added and mixed by rotation at 25°C for 10 minutes. The mRNA-protein complexes were then collected and washed with 10 μL of HBST (50 mM Hepes-KOH (pH 7.5), 300 mM NaCl, 0.05% (v / v) Tween 20) for 10 seconds.

[0090] 1x PCR dNTPs (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton X-100, 2 mM MgSO4, 0.22 mM dNTPs) were added to 0.4 pmol of unrecovered mRNA-protein complex (before recovery) and the total amount of recovered mRNA-protein complex (after recovery) to make a total volume of 1000 μL. Take 85 μL from there, add equal volume of 2x PCR reaction solution (10 mM Tris-HCl pH 8.4, 100 mM KCl, 0.1% (v / v) Triton SD8barcode2, 12.5 μM HATagR23+3, 12.5 μM HATagR23+2, 12.5 μM HATagR23+1, 12.5 μM HATagR23) or (50 μM SDcatbarcode9 or SDcatbarcode10, 12.5 μM HATagR23+3, 12.5 μM HATagR23+2, 12.5 μM 1.275 μL of HATagR23+1 (12.5 μM HATagR23) was added, and 8 cycles of PCR were performed. After PCR, the DNA was treated with phenol and chloroform and precipitated with isopropanol. The DNA was sequenced using a next-generation sequencer (Macrogen Japan).

[0091] Test Example 1. Data Analysis and Evaluation of Screening Results for C-Terminal Random Sequences. As shown in Figure 1A, a mixed DNA library was created by adding type I (VVNVVNTAG) and type II (VVNVVNTAGN) C-terminal random sequences to the upstream sequence (monobody or anticalin). This DNA library was used as a template to transcribe mRNA, and mRNA-protein complexes were generated using a TRAP reaction system. These complexes could be recovered using streptavidin beads with biotin modified at the N-terminus of the protein. Both the pre- and post-recovery libraries were reverse-transcribed to cDNA and sequenced using a next-generation sequencer. Sequence analysis yielded over 20 million reads for each library. While the mixed library theoretically contains 7,056 different sequences, at least one read was obtained for each sequence. Of these, sequences with 100 or more reads both before and after collection were considered valid for future analysis (more than 99.9% of all but four types for Monobody, and more than 99.8% of all but nine types for Anticalin).

[0092] First, the enrichment rate was calculated. Figure 4 shows a heat map in which the enrichment rate of each C-terminal sequence in the monobody library is represented by color. A diagram was created in which the enrichment rate of each C-terminal sequence in monobody and anticalin was plotted (Figure 2A). There was a strong correlation between the enrichment rate of each C-terminal sequence in the library in which the upstream sequence was monobody and the library in which the upstream sequence was anticalin (R 2 = 0.83). This result suggests the possibility of obtaining a C-terminal sequence that exhibits general-purpose high display efficiency.

[0093] To confirm the correlation between enrichment rate and display efficiency, 19 C-terminal sequences that showed various enrichment rates were selected for display efficiency measurement (Table 3). DNA was prepared by inserting these sequences into the C-terminus of a monobody, and the sequence was transcribed into mRNA (named McX). The transcribed mRNA was reacted in a TRAP reaction system, and the display efficiency was measured. As a result, it was found that the enrichment rate in the library with a monobody as the upstream sequence was strongly correlated with the display efficiency (R2 = 0.83) (Figure 2B). In other words, the enrichment rate calculated by this method can be used to indirectly evaluate the display efficiency of the C-terminal sequence.

[0094]

[0095] Furthermore, the sequences of Codon 1 with an enrichment rate of 3.2 or higher in at least one of the monobody and anticalin were GGC, CGT, and GGT, and the sequences of Codon 2 with an enrichment rate of 3.2 or higher in at least one of the monobody and anticalin were CGA, AGC, AGA, ACA, CGT, AGT, GCA, AGG, GGT, CGC, GCT, GGC, CGG, ACT, GAT, and GAC. The Codon 1-Codon 2 sequences with an enrichment ratio of 2.8 or higher for both Monobody and Anticalin were GGCCGA, GGCAGA, GGCGCA, GGTAGA, GGCAGT, GGCAGC, GGCACA, GGCCGT, GGCGCT, GGCGAT, GGCACT, GGTCGA, GGCAGG, GGCACG, GGTGAC, GGTAGG, CGTCGA, GGTAGT, GGTCGT, GGCGGT, GGACGA, GGTGGT, GGTACA, GGTCGC, AATCGA, GGTAGC, and GCGCGA. The Codon 1-Codon 2 sequences with an enrichment ratio of 3.0 or higher for both Monobody and Anticalin were GGCCGA, GGCAGA, GGTAGA, GGCACA, GGCCGT, GGCAGT, GGCAGC, GGCAGG, GGTCGA, GGCGCT, GGCACT, GGCGCA, and GGTAGG. The Codon 1-Codon 2 sequences with an enrichment rate of 3.2 or higher for both Monobody and Anticalin were GGCCGA, GGCAGA, GGTAGA, GGCCGT, GGCAGT, GGCAGC, GGTCGA, GGCGCT, and GGCACT. A polynucleotide in which a polypeptide coding sequence or a polypeptide coding sequence insertion site, Codon 1, Codon 2, and a stop codon are arranged in this order, and Codon 1 and Codon 2 are adjacent to each other, can exhibit high display efficiency in polynucleotide display methods.

[0096] Test Example 2: Evaluation of the Versatile High Display Efficiency of the Obtained C-Terminal Sequence Previous experiments used monobody WT, which has a constant overall sequence. However, when actually obtaining functional molecules using evolutionary molecular engineering techniques, a monobody library with high diversity is used, which is achieved by randomizing the two loop structures that serve as binding sites. Therefore, a sequence cannot be considered effective unless it shows high display efficiency not only for monobody WT but also for a monobody library containing random sequences. Therefore, we decided to confirm whether the obtained C-terminal sequence can be applied to a monobody library. The monobody library used in this study was designed and constructed based on previous research. The monobody library contains random sequences in the two loops, and these random sequences are designed to contain no stop codons. DNA was constructed by introducing the highest enrichment rate c1, c16 at position 194, and c13 at position 2448 into the C-terminus of the monobody library, and this was transcribed into mRNA (named MRcX). The transcribed mRNA was reacted in a TRAP reaction system for an optimized time, and the display efficiency was measured. The results showed that MRc1 and MRc16, which were in the top 3% of enrichment, had significantly higher display efficiency than MRc13 (MRc1: 14.6%, MRc16: 14.1%, MRc13: 6.91%) (Figure 3A). Therefore, selecting a C-terminal sequence with an enrichment rate within the top 3% will result in high display efficiency even for libraries with random sequences at the binding site.

[0097] However, the high display efficiency even for the monobody library may be due to the 78–84% homology with Monobody WT. Therefore, we constructed DNA containing the same three C-terminal sequences at the C-terminus of Anticalin, another artificial antibody scaffold with no sequence homology, and transcribed it into mRNA (designated LcX). The transcribed mRNA was reacted in a TRAP reaction system and the display efficiency was measured. The results showed that Lc1 and Lc16, which were in the top 3% of enrichment, had significantly higher display efficiency than Lc13 (Lc1: 18.0%, Lc16: 17.4%, Lc13: 4.85%) (Figure 3B). Therefore, selecting a C-terminal sequence with an enrichment rate within the top 3% can be expected to achieve high display efficiency even for other artificial antibody scaffolds with completely different sequences.

[0098] Next, we investigated whether the C-terminal sequences obtained in this screening could be applied to macrocyclic peptide libraries, which are expected to be a new drug discovery modality. The macrocyclic peptide library used in this study contained a 15-residue random sequence, with N-chloroacetyl-L-phenylalanine and cysteine ​​residues at both ends designed to trigger cyclization. The random sequence was designed to contain no stop codons. DNA containing the same three C-terminal sequences as described above was constructed at the C-terminus of the macrocyclic peptide library and transcribed into mRNA (designated PRcX). The transcribed mRNA was reacted in a TRAP reaction system, and the display efficiency was measured. The results showed that PRc1 and PRc16 had significantly higher display efficiency than PRc13 (PRc1: 16.5%, PRc16: 14.0%, PRc13: 5.79%) (Figure 3C). Therefore, selecting C-terminal sequences with enrichment rates within the top 3% would also result in high display efficiency for macrocyclic peptide libraries.

[0099] Test Example 3: Screening for N-Terminal Random Sequences. The enrichment rate was measured for N-terminal random sequences adjacent to AUG, in the same manner as for C-terminal random sequences (Figures 5 and 6). As with the screening for C-terminal random sequences, the enrichment rate varied depending on the sequence, and some sequences exhibited high enrichment rates. Furthermore, when comparing two monobodies with different upstream sequences containing an SD sequence, the enrichment rate was found to depend on the combination of the SD sequence and the N-terminal random sequence. Furthermore, when comparing a monobody and an anticain with the same upstream sequence containing an SD sequence, the enrichment rate was found to depend on the combination of the protein and the N-terminal random sequence. The enrichment rate here reflects the efficiency of translation initiation, which is important for protein expression. Therefore, by determining the enrichment rate for a given protein using this method, it is possible to identify sequences that can control the expression of that protein. This information will enable precise control of protein expression and be useful for highly efficient protein production.

[0100] Test Example 4. Data analysis and evaluation of screening results for C-terminal random sequences 2 A mixed DNA library was created in which a type I (NNNNNNTAG) C-terminal random sequence was added to the upstream sequence (Monobody). Screening was performed using this library in the same manner as in Test Example 1, and the enrichment rate was calculated. Figure 7 shows a heat map in which the enrichment rate of each C-terminal sequence in the Monobody library is represented by color. The correspondence between color and enrichment rate is the same as in Figure 4.

[0101] Codon 1 sequences with relatively high enrichment rates were AAA, GGC, CGT, and GGT, and codon 2 sequences with relatively high enrichment rates were ACA, AGA, AGC, AGG, AGT, ATG, CCA, CCG, CCT, CGA, CGC, CGT, CTA, and CTG.

Claims

1. (a) binding a polynucleotide-polypeptide complex obtained by translating a polynucleotide comprising a polypeptide coding sequence and a random sequence in a cell-free translation system to a solid phase via a modifying substance on the polypeptide in the polynucleotide-polypeptide complex; (b) measuring and calculating the ratio (enrichment rate) of the frequency of occurrence of each random sequence in the polynucleotide-polypeptide complex bound to the solid phase to the frequency of occurrence of each random sequence in the polynucleotide, and selecting a random sequence using the obtained enrichment rate as an index.

2. The screening method according to claim 1 , wherein in the step (b), a random sequence having a high enrichment rate is selected as a sequence that improves display efficiency.

3. The screening method according to claim 1 or 2, wherein in the step (b), random sequences having the enrichment rate in the top 10% are selected as sequences that improve the display efficiency.

4. The method of any one of claims 1 to 3, wherein the modifying substance is at least one selected from the group consisting of biotin, a peptide tag, and a substance containing a readily reactive group.

5. The screening method according to any one of claims 1 to 4, wherein the random sequence is located downstream of the polypeptide coding sequence.

6. The screening method according to claim 5 , wherein a linker sequence is disposed between the random sequence and the polypeptide coding sequence.

7. The screening method according to claim 5 or 6, wherein a stop codon is located adjacent to or within the random sequence.

8. A reagent for a polynucleotide display method comprising a polynucleotide, the polynucleotide comprises a polypeptide coding sequence or a site for inserting a polypeptide coding sequence, sequence 1 which is 3 bases long, sequence 2 which is 3 bases long, and a stop codon, which are arranged in the order of the polypeptide coding sequence or the site for inserting a polypeptide coding sequence, sequence 1, sequence 2, and the stop codon from upstream, sequence 1 and sequence 2 are adjacent to each other, sequence 2 and the stop codon are adjacent to each other, and sequence 1 is GGC, CGT, GGT, or AAA, and / or sequence 2 is CGA, AGC, AGA, ACA, CGT, AGT, GCA, AGG, GGT, CGC, GCT, GGC, CGG, ACT, GAT, GAC, ATG, CCA, CCG, CCT, CTA, or CTG, and The polynucleotide display method is a polynucleotide display method using a cell-free translation system that is a prokaryotic cell translation system. reagent.

9. 9. The reagent of claim 8, wherein sequence 1 is GGC, CGT, GGT, or AAA, and sequence 2 is CGA, AGC, AGA, ACA, CGT, AGT, GCA, AGG, GGT, CGC, GCT, GGC, CGG, ACT, GAT, GAC, ATG, CCA, CCG, CCT, CTA, or CTG.

10. The reagent according to claim 8 or 9, wherein the consecutive sequences of sequence 1 and sequence 2 are GGCCGA, GGCAGA, GGCGCA, GGTAGA, GGCAGT, GGCAGC, GGCACA, GGCCGT, GGCGCT, GGCGAT, GGCACT, GGTCGA, GGCAGG, GGCACG, GGTGAC, GGTAGG, CGTCGA, GGTAGT, GGTCGT, GGCGGT, GGACGA, GGTGGT, GGTACA, GGTCGC, AATCGA, GGTAGC, or GCGCGA.